{"nctId":"NCT04508621","briefTitle":"A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia","startDateStruct":{"date":"2020-07-22","type":"ACTUAL"},"conditions":["Fibromyalgia"],"count":514,"armGroups":[{"label":"TNX-102 SL Tablet, 5.6 mg","type":"EXPERIMENTAL","interventionNames":["Drug: TNX-102 SL"]},{"label":"Placebo SL Tablet","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo SL Tablet"]}],"interventions":[{"name":"TNX-102 SL","otherNames":["Low dose cyclobenzaprine sublingual tablets"]},{"name":"Placebo SL Tablet","otherNames":["Placebo sublingual tablets"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient is male or female 18 to 65 years of age, inclusive.\n* The patient has a diagnosis of primary FM as defined by the 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (American College of Rheumatology Preliminary Diagnostic Criteria)\n* The in clinic 7-day recall NRS average daily pain intensity score at Screening Visit within protocol defined range.\n\nExclusion Criteria:\n\n\\- History of or evidence for a diagnosis of borderline personality disorder (BPD).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.","description":"Patients provide a daily numeric assessment of their average pain (24-hour recall), via an electronic diary, using an 11-point NRS. Scores range from 0 (no pain) to 10 (worst possible pain).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":null},{"groupId":"OG001","value":"-1.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of \"Very Much Improved\" or \"Much Improved\"","description":"The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates a much worse outcome.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 14 in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score.","description":"The FIQ-R is a validated questionnaire. Scores on the symptoms domain range from 0 to 100 where a higher score means worse outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.3","spread":null},{"groupId":"OG001","value":"-12.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 14 in the FIQ-R Function Domain Score","description":"The FIQ-R is a validated questionnaire. Score on the function domain range from 0 to 90 where a higher score means worse outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.8","spread":null},{"groupId":"OG001","value":"-8.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 14 in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance","description":"The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":null},{"groupId":"OG001","value":"-5.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 14 in the PROMIS Score for Fatigue","description":"The PROMIS fatigue short form 8a consist of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":null},{"groupId":"OG001","value":"-5.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 14 in the Weekly Average of the Daily Diary Assessment of Sleep Quality","description":"Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":null},{"groupId":"OG001","value":"-1.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":256},"commonTop":["Hypoaesthesia oral","Product taste abnormal","Oral discomfort","Tongue discomfort"]}}}